Published in J Neuroimmunol on June 12, 2013
Estrogen receptor (ER) β expression in oligodendrocytes is required for attenuation of clinical disease by an ERβ ligand. Proc Natl Acad Sci U S A (2013) 0.86
Disease Modifying Potential of Glatiramer Acetate in Huntington's Disease. J Huntingtons Dis (2014) 0.76
Side effect profile similarities shared between antidepressants and immune-modulators reveal potential novel targets for treating major depressive disorders. BMC Pharmacol Toxicol (2016) 0.75
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
Neurotrophins and their receptors: a convergence point for many signalling pathways. Nat Rev Neurosci (2003) 7.44
Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J Cell Biol (2009) 5.65
Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat Rev Neurosci (2008) 4.91
Inflammation in neurodegenerative diseases. Immunology (2010) 3.22
Potential therapeutic uses of BDNF in neurological and psychiatric disorders. Nat Rev Drug Discov (2011) 2.65
Targeted disruption of the trkB neurotrophin receptor gene results in nervous system lesions and neonatal death. Cell (1993) 2.52
How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann Neurol (2006) 2.38
TrkB has a cell-autonomous role in the establishment of hippocampal Schaffer collateral synapses. J Neurosci (2005) 2.21
Isoform-specific expression and function of neuregulin. Development (1997) 2.10
The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice. Proc Natl Acad Sci U S A (2005) 1.44
Sex differences in experimental autoimmune encephalomyelitis in multiple murine strains. J Neuroimmunol (2004) 1.34
The neuregulin signaling pathway and schizophrenia: from genes to synapses and neural circuits. Brain Res Bull (2010) 1.34
BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells? Brain (2002) 1.33
Neuregulins: versatile growth and differentiation factors in nervous system development and human disease. Brain Res Rev (2006) 1.32
Function of neurotrophic factors beyond the nervous system: inflammation and autoimmune demyelination. Crit Rev Immunol (2009) 1.27
Neuregulin-ErbB signaling promotes microglial proliferation and chemotaxis contributing to microgliosis and pain after peripheral nerve injury. J Neurosci (2010) 1.26
Multiple sclerosis - candidate mechanisms underlying CNS atrophy. Trends Neurosci (2010) 1.19
Stimulation of the neurotrophin receptor TrkB on astrocytes drives nitric oxide production and neurodegeneration. J Exp Med (2012) 1.15
Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action. CNS Drugs (2011) 1.15
A critical appraisal of treatment decisions in multiple sclerosis--old versus new. Nat Rev Neurol (2011) 1.13
Neuregulins and the neuromuscular system: 10 years of answers and questions. J Neurocytol (2004) 1.12
Axo-glial antigens as targets in multiple sclerosis: implications for axonal and grey matter injury. J Mol Med (Berl) (2010) 1.11
A common pattern of persistent gene activation in human neocortical epileptic foci. Ann Neurol (2005) 1.10
IL-10 is essential for disease protection following intranasal peptide administration in the C57BL/6 model of EAE. J Neuroimmunol (2006) 1.09
Neurotrophins in cell survival/death decisions. Adv Exp Med Biol (1999) 1.08
Rapid axoglial signaling mediated by neuregulin and neurotrophic factors. J Neurosci (2004) 1.08
Demyelination arrest and remyelination induced by glatiramer acetate treatment of experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A (2008) 1.03
The neuregulin, glial growth factor 2, diminishes autoimmune demyelination and enhances remyelination in a chronic relapsing model for multiple sclerosis. Proc Natl Acad Sci U S A (1998) 1.03
Neuregulin expression at neuromuscular synapses is modulated by synaptic activity and neurotrophic factors. J Neurosci (2002) 1.01
Expression patterns of transmembrane and released forms of neuregulin during spinal cord and neuromuscular synapse development. Development (1999) 0.99
Glatiramer acetate treatment of multiple sclerosis: an immunological perspective. J Immunol (2011) 0.98
Increasing local levels of neuregulin (glial growth factor-2) by direct infusion into areas of demyelination does not alter remyelination in the rat CNS. Eur J Neurosci (2003) 0.95
Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis. J Neuroimmunol (2012) 0.95
Neurotrophic factors increase neuregulin expression in embryonic ventral spinal cord neurons. J Neurosci (1997) 0.93
Critical period of axoglial signaling between neuregulin-1 and brain-derived neurotrophic factor required for early Schwann cell survival and differentiation. J Neurosci (2011) 0.92
p75NTR and apoptosis: Trk-dependent and Trk-independent effects. Trends Neurosci (1997) 0.89
Neurotrophic cross-talk between the nervous and immune systems: relevance for repair strategies in multiple sclerosis? J Neurol Sci (2007) 0.88
Brain-derived neurotrophic factor and TrkB receptor in experimental autoimmune encephalomyelitis and multiple sclerosis. J Neurol Sci (2009) 0.86
Aberrant neuregulin 1 signaling in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol (2012) 0.85
Experimental autoimmune demyelinating diseases: experimental allergic encephalomyelitis and experimental allergic neuritis. Biomedicine (1975) 0.85
Neuregulin in neuron/glial interactions in the central nervous system. GGF2 diminishes autoimmune demyelination, promotes oligodendrocyte progenitor expansion, and enhances remyelination. Adv Exp Med Biol (1999) 0.84
Targeting human epidermal growth factor receptor signaling with the neuregulin's heparin-binding domain. J Biol Chem (2009) 0.84
Neuroinflammation and neuroprotection: an update on (future) neurotrophin-related strategies in multiple sclerosis treatment. Curr Med Chem (2011) 0.83
Central nervous system rather than immune cell-derived BDNF mediates axonal protective effects early in autoimmune demyelination. Acta Neuropathol (2011) 0.83
Neuregulin and erbB receptor expression in normal and diseased human white matter. J Neuroimmunol (1999) 0.81
Neuroprotection and repair by neurotrophic and gliotrophic factors in multiple sclerosis. Neurology (2007) 0.79
Long-term therapy with glatiramer acetate in multiple sclerosis: effect on T-cells. Mult Scler (2001) 0.78
Neuregulin-1 type III determines the ensheathment fate of axons. Neuron (2005) 4.19
Neurocysticercosis: A natural human model of epileptogenesis. Epilepsia (2014) 2.11
Asymmetric flaccid paralysis: a neuromuscular presentation of West Nile virus infection. Ann Neurol (2003) 1.72
Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis. Arch Neurol (2011) 1.47
Neuregulins: versatile growth and differentiation factors in nervous system development and human disease. Brain Res Rev (2006) 1.32
Neuregulin-ErbB signaling promotes microglial proliferation and chemotaxis contributing to microgliosis and pain after peripheral nerve injury. J Neurosci (2010) 1.26
Epilepsy biomarkers. Epilepsia (2013) 1.19
Activity-dependent human brain coding/noncoding gene regulatory networks. Genetics (2012) 1.13
Following nerve injury neuregulin-1 drives microglial proliferation and neuropathic pain via the MEK/ERK pathway. Glia (2011) 1.11
A common pattern of persistent gene activation in human neocortical epileptic foci. Ann Neurol (2005) 1.10
Activity-dependent gene expression correlates with interictal spiking in human neocortical epilepsy. Epilepsia (2007) 1.08
Rapid axoglial signaling mediated by neuregulin and neurotrophic factors. J Neurosci (2004) 1.08
Role of neuropoietic cytokines in development and progression of diabetic polyneuropathy: from glucose metabolism to neurodegeneration. Exp Diabesity Res (2003) 1.04
Layer-specific CREB target gene induction in human neocortical epilepsy. J Neurosci (2012) 1.01
Mechanisms of action of adrenocorticotropic hormone and other melanocortins relevant to the clinical management of patients with multiple sclerosis. Mult Scler (2012) 0.99
Accuracy of cDNA microarray methods to detect small gene expression changes induced by neuregulin on breast epithelial cells. BMC Bioinformatics (2004) 0.99
Development of an autocrine neuregulin signaling loop with malignant transformation of human breast epithelial cells. Cancer Res (2004) 0.98
High inter-reviewer variability of spike detection on intracranial EEG addressed by an automated multi-channel algorithm. Clin Neurophysiol (2011) 0.97
Finding a better drug for epilepsy: preclinical screening strategies and experimental trial design. Epilepsia (2012) 0.95
Focal reduction of neuronal glutamate transporters in human neocortical epilepsy. Epilepsia (2007) 0.93
Critical period of axoglial signaling between neuregulin-1 and brain-derived neurotrophic factor required for early Schwann cell survival and differentiation. J Neurosci (2011) 0.92
Distinct immune regulation of the response to H-2b restricted epitope of MOG causes relapsing-remitting EAE in H-2b/s mice. J Neuroimmunol (2003) 0.92
Specific structural features of heparan sulfate proteoglycans potentiate neuregulin-1 signaling. J Biol Chem (2004) 0.91
NT-3 and CNTF exert dose-dependent, pleiotropic effects on cells in the immature dorsal root ganglion: neuregulin-mediated proliferation of progenitor cells and neuronal differentiation. Dev Biol (2006) 0.90
Neurotrophins induce neuregulin release through protein kinase Cdelta activation. J Biol Chem (2009) 0.90
Myasthenic crisis: guidelines for prevention and treatment. J Neurol Sci (2007) 0.89
Epilepsy therapy development: technical and methodologic issues in studies with animal models. Epilepsia (2013) 0.88
Differential distribution of neuregulin in human brain and spinal fluid. Brain Res (2008) 0.87
Electrical, molecular and behavioral effects of interictal spiking in the rat. Neurobiol Dis (2012) 0.86
WONOEP appraisal: new genetic approaches to study epilepsy. Epilepsia (2014) 0.85
Aberrant neuregulin 1 signaling in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol (2012) 0.85
Ectopic germinal centers, BAFF and anti-B-cell therapy in myasthenia gravis. Autoimmun Rev (2013) 0.85
Targeting human epidermal growth factor receptor signaling with the neuregulin's heparin-binding domain. J Biol Chem (2009) 0.84
ACTH protects mature oligodendroglia from excitotoxic and inflammation-related damage in vitro. Glia (2013) 0.84
Myasthenia gravis patients, but not healthy subjects, recognize epitopes that are unique to the epsilon-subunit of the acetylcholine receptor. J Neuroimmunol (2004) 0.84
Other demyelinating diseases. Adv Neurol (2006) 0.83
B-cell-activating factor and autoimmune myasthenia gravis. Autoimmune Dis (2011) 0.82
Myasthenia gravis. Curr Treat Options Neurol (2010) 0.81
Adrenocorticotropin hormone 1-39 promotes proliferation and differentiation of oligodendroglial progenitor cells and protects from excitotoxic and inflammation-related damage. J Neurosci Res (2014) 0.80
Cytokines reduce toxic effects of ethanol on oligodendroglia. Neurochem Res (2011) 0.79
Adoptive transfer of myelin basic protein-induced experimental autoimmune encephalomyelitis between SJL and B10.S mice: correlation of priming milieus with susceptibility and resistance phenotypes. J Neuroimmunol (2006) 0.79
Synergistic effects of neuregulin and agrin on muscle acetylcholine receptor expression. Mol Cell Neurosci (2004) 0.79
The tanapoxvirus 15L protein is a virus-encoded neuregulin that promotes viral replication in human endothelial cells. J Virol (2012) 0.77
The American Academy of Neurology's top five Choosing Wisely recommendations. Neurology (2013) 0.77
Electrospinning of matrigel to deposit a basal lamina-like nanofiber surface. J Biomater Sci Polym Ed (2010) 0.77
Activation of IL-1 signaling pathway in Schwann cells during diabetic neuropathy. Ann N Y Acad Sci (2002) 0.77
Systems biology of human epilepsy applied to patients with brain tumors. Epilepsia (2013) 0.76
Glatiramer acetate in the treatment of multiple sclerosis. Neuropsychiatr Dis Treat (2007) 0.76
"Rebooting" the immune system with cyclophosphamide: taking risks for a "cure"? Ann Neurol (2003) 0.75
The two articles published in the Journal of Neurological Sciences by Dr. Oka. J Neurol Sci (2008) 0.75
Introduction to the special section on Robert Lisak's contributions to neuroimmunology. J Neurol Sci (2013) 0.75
Approaches to neuroprotective strategies in multiple sclerosis. Expert Opin Pharmacother (2010) 0.75
Cytokines decrease expression of interleukin-6 signal transducer and leptin receptor in central nervous system glia. J Neurosci Res (2009) 0.75
At jeopardy: the NIH as we know it. Arch Neurol (2003) 0.75
Differences between the epsilon and gamma subunits of the acetylcholine receptor (AChR) may be significant in autoimmune myasthenia gravis. Ann N Y Acad Sci (2003) 0.75
Farewell editorial. J Neurol Sci (2013) 0.75
Pica-associated cerebral edema in an adult. J Neurol Sci (2004) 0.75
At jeopardy: the NIH as we know it. Neurorehabil Neural Repair (2003) 0.75
Myasthenia gravis. Autoimmune Dis (2012) 0.75
Activation of microglial neuregulin1 signaling in the corticospinal tracts of ALS patients with upper motor neuron signs. Amyotroph Lateral Scler Frontotemporal Degener (2013) 0.75
The immunopathogenesis of Guillain-Barré syndrome. Clin Adv Hematol Oncol (2010) 0.75
Estimation of resting state effective connectivity in epilepsy using direct-directed transfer function. Conf Proc IEEE Eng Med Biol Soc (2016) 0.75
Treatment of patients with multiple sclerosis with anti-herpes virus therapy. Curr Neurol Neurosci Rep (2002) 0.75